From molecular biology to pharmacogenetics: A review of the literature on antidepressant treatment and suggestions of possible candidate genes

Psychopharmacology

Volumn 174, Issue 4, 2004, Pages 490-503

  Serretti, Alessandro ^a   Artioli, Paola ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antidepressant; Bipolar disorder; Depression; Pharmacogenetics; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; CATECHOLAMINE; CITALOPRAM; DOPAMINE; FLUOXETINE; FLUVOXAMINE; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE; NEUROKININ; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUBSTANCE P; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN HYDROXYLASE; VENLAFAXINE;

ADRENERGIC SYSTEM; BETA CHAIN; CATECHOLAMINE SYNTHESIS; CAUCASIAN; CLINICAL RESEARCH; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG RESPONSE; GENETIC VARIABILITY; HUMAN; MEDICAL LITERATURE; METHODOLOGY; MOLECULAR BIOLOGY; MONOAMINE METABOLISM; MOOD DISORDER; NEUROTRANSMISSION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PSYCHOPHARMACOTHERAPY; REVIEW; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 4344686766     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1822-x     Document Type: Review

References (146)

1. American Psychiatric Association (2000) Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 157:1-45
2. Arias B, Catalan R, Gasto C, Imaz ML, Gutierrez B, Pintor L, Fananas L (2001) Genetic variability in the promoter region of the serotonin transporter gene is associated with clinical remission of major depression after long term treatment with citalopram. World Federation of Societies of Biological Psychiatry, vol 2(1). World Journal of Biological Psychiatry, Berlin, Germany, p 9S
3. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L (2002) Association between serotoninergic genes. In: Tsuang M (ed) Xth world congress of psychiatric genetics, vol 114. Wiley-Liss, Brussels, p 751
4. Artioli P, Serretti A, Lattuada E, Lorenzi C, Lilli R, Smeraldi E (2002) Clinical and genetic features of antidepressant induced mania in bipolar disorder. In: Tsuang M (ed) Xth World Congress of Psychiatric Genetics. Wiley-Liss, Brussels, p 755
5. Baghai TC, Schule C, Zwanzger P, Minov C, Schwarz MJ, de Jonge S, Rupprecht R, Bondy B (2001) Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatry 6:258-259
6. 2 receptors. Nature 377:424-428
7. Berry MD, Juorio AV, Paterson IA (1994) The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog Neurobiol 42:375-391
8. Blakely RD (2001) Physiological genomics of antidepressant targets: keeping the periphery in mind. J Neurosci 21:8319-8323
9. Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-226
10. Bloom FE, Kupfer DJ (1995) Psychopharmacology: the fourth generation of progress. Raven Press, New York
11. Boularand S, Darmon MC, Ganem Y, Launay JM, Mallet J (1990) Complete coding sequence of human tryptophan hydroxylase. Nucl Acid Res 18:4257
12. Boyer PA, Skolnick P, Fossom LH (1998) Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J Mol Neurosci 10:219-233
13. Brahe C, Bannetta P, Meera Khan P, Arwert F, Serra A (1986) Assignment of the catechol-O-methyltransferase gene to human chromosome 22 in somatic cell hybrids. Hum Genet 74:230-234
14. Buck KJ, Amara SG (1994) Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc Natl Acad Sci USA 91:12584-12588
15. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, Trendelenburg U (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136
16. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880
17. Cote F, Schussler N, Boularand S, Peirotes A, Thevenot E, Mallet J, Vodjdani G (2002) Involvement of NF-Y and Sp1 in basal and cAMP-stimulated transcriptional activation of the tryptophan hydroxylase (TPH) gene in the pineal gland. J Neurochem 81:673-685
18. Craig SP, Boularand S, Darmon MC, Mallet J, Craig IW (1991) Localization of human tryptophan hydroxylase (TPH) to chromosome 11p15.3-p14 by in situ hybridization. Cytogenet Cell Genet 56:157-159
19. Crissman AM, Makhay MM, O'Donnell JM (2001) Discriminative stimulus effects of centrally administered isoproterenol in rats: mediation by beta-1 adrenergic receptors. Psychopharmacology 154:70-75
20. 1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Hum Psychopharmacol 15:113-135
21. Cryan JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA (2001) Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther 298:651-657
22. Cubells JF, Kobayashi K, Nagatsu T, Kidd KK, Kidd JR, Calafell F, Kranzler HR, Ichinose H, Gelernter J (1997) Population genetics of a functional variant of the dopamine beta-hydroxylase gene (DBH). Am J Med Genet 74:374-379
23. Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D, Lilli R, Lorenzi C, Smeraldi E (2002) Influence of monoamine oxydase A and serotonin receptor 2A polymorphisms in SSRIs antidepressant activity. Int J Neuropsychopharmacol 5:27-35
24. De Luca V, Mundo E, Trakalo J, Wong GW, Kennedy JL (2003) Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania. Pharmacogenomics J 3:297-299
25. A promoter-associated variable number tandem repeat. Hum Genet 105:542-551
26. Dong J, Blier P (2001) Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology 155:52-57
27. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB (2003) The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology 4:4
28. Elena Castro M, Diaz A, del Olmo E, Pazos A (2003) Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT(1A) receptors in rat brain. Neuropharmacology 44:93-101
29. Ewart GD, Cannell D, Cox GB, Howells AJ (1994) Mutational analysis of the traffic ATPase (ABC) transporters involved in uptake of eye pigment precursors in Drosophila melanogaster. Implications for structure-function relationships. J Biol Chem 269:10370-10377
30. Froger N, Gardier AM, Moratalla R, Alberti I, Lena I, Boni C, De Felipe C, Rupniak NM, Hunt SP, Jacquot C, Hamon M, Lanfumey L (2001) 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 21:8188-8197
31. Fryer RM, Randall J, Yoshida T, Hsiao LL, Blumenstock J, Jensen KE, Dimofte T, Jensen RV, Gullans SR (2002) Global analysis of gene expression: methods, interpretation, and pitfalls. Exp Nephrol 10:64-74
32. Fuciarelli M, Vienna A, Paba E, Bastianini A, Sansonetti B, Capucci E, Destefano GF (1997) PI, GC, HP, and TF serum protein polymorphisms in Siena, Tuscany, Italy, with a review of data for Italy. Am J Hum Biol 9:629-646
33. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG (1999) Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283:397-401
34. Gelernter J, Kruger S, Kidd KK, Amara S (1993) TaqI RFLP at norepinephrine transporter protein (NET) locus. Hum Mol Genet 2:820
35. Gilmor ML, Owens MJ, Nemeroff CB (2002) Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 159:1702-1710
36. Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42:383-390
37. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612
38. Grossman MH, Emanuel BS, Budarf ML (1992) Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2. Genomics 12:822-825
39. Grunhage F, Schulze TG, Muller DJ, Lanczik M, Franzek E, Albus M, Borrmann-Hassenbach M, Knapp M, Cichon S, Maier W, Rietschel M, Propping P, Nothen MM (2000) Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1). Mol Psychiatry 5:275-282
40. Gur E, Dremencov E, Garcia F, Van de Kar LD, Lerer B, Newman ME (2002) Functional effects of chronic electroconvulsive shock on serotonergic 5-HT(1A) and 5-HT(1B) receptor activity in rat hippocampus and hypothalamus. Brain Res 952:52-60
41. Harkin A, Connor TJ, Walsh M, St John N, Kelly JP (2003) Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 44:616-623
42. Heiberg IL, Wegener G, Rosenberg R (2002) Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 134:479-484
43. Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, Lesch P (1996) Allelic variation of human serotonin trasporter gene expression. J Neurochem 66:2621-2624
44. Hemrick-Luecke SK, Snoddy HD, Fuller RW (1994) Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci 55:479-83
45. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478
46. Holmes A, Murphy DL, Crawley JN (2002) Reduced aggression in mice lacking the serotonin transporter. Psychopharmacology 161:160-167
47. Holmes A, Yang RJ, Lesch KP, Crawley JN, Murphy DL (2003) Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 10:10
48. Hong CJ, Wang YC, Tsai SJ (2002) Association study of angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders. J Neural Transm 109:1209-1214
49. Ito K, Yoshida K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K (2002) A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 111:235-239
50. Johnson M, Hanson GR, Gibb JW (1989) Characterization of acute N-ethyl-3,4-methylenedioxyamphetamine (MDE) action on the central serotonergic system. Biochem Pharmacol 38:4333-4338
51. Jonsson EG, Goldman D, Spurlock G, Gustavsson JP, Nielsen DA, Linnoila M, Owen MJ, Sedvall GC (1997) Tryptophan hydroxylase and catechol-O- methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatr Clin Neurosci 247:297-302
52. 2a receptor genes. Am J Psychiatry 155:1275-1277
53. 1a receptor gene and association analysis in schizophrenia. Am J Med Genet 81:434-439
54. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, Carroll BJ (2000) Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11:215-219
55. Kim SW, Park SY, Hwang O (2002) Up-regulation of tryptophan hydroxylase expression and serotonin synthesis by sertraline. Mol Pharmacol 61:778-785
56. Kirigiti P, Yang YF, Li X, Li B, Midson CN, Machida CA (2000) Rat beta 1-adrenergic receptor regulatory region containing consensus AP-2 elements recognizes novel transactivator proteins. Mol Cell Biol Res Commun 3:181-192
57. Kirov G, Lowry CA, Stephens M, Oldfield S, O'Donovan MC, Lightman SL, Owen MJ (2001) Screening ABCG1, the human homologue of the Drosophila white gene, for polymorphisms and association with bipolar affective disorder. Mol Psychiatry 6:671-677
58. Kobilka BK, Frielle T, Collins S, Yang-Feng T, Kobilka TS, Francke U, Lefkowitz RJ, Caron MG (1987) An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature 329:75-79
59. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, Meltzer HY, Sibley DR, Roth BL, Hamblin MW (1996) Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 66:47-56
60. Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T, Hirose T, Nanko S (1997) Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 2:457-462
61. Lee ST, Nicholls RD, Jong MT, Fukai K, Spritz RA (1995) Organization and sequence of the human P gene and identification of a new family of transport proteins. Genomics 26:354-363
62. 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 23:8788-8799
63. Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL, Riederer P (1994) Organization of the human serotonin transporter gene. J Neural Transm [Gen Sect] 95:157-162
64. Lesch K, Bengel D, Heils A, Sabol S, Greenberg B, Petri S, Benjamin J, Muller C, Hamer D, Murphy D (1996) Association of anxiety-related traits with a polymorpnismin the serotonin transporter gene regulatory region. Science 274:1527-1530
65. Leszczynska-Rodziewicz A, Czerski PM, Kapelski P, Godlewski S, Dmitrzak-Weglarz M, Rybakowski J, Hauser J (2002) A polymorphism of the norepinephrine transporter gene in bipolar disorder and schizophrenia: lack of association. Neuropsychobiology 45:182-185
66. Lorang D, Amara SG, Simerly RB (1994) Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci 14:4903-4914
67. Maes M, Meltzer HY (1995) The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 933-944
68. Mancama D, Kerwin RW (2003) Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs 17:143-151
69. 1-adrenergic receptor. J Biol Chem 274:12670-12674
70. Miller GM, Madras BK (2002) Polymorphisms in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry 7:44-55
71. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P, Rupprecht R, Bondy B (2001) Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 303:119-122
72. Morino H, Kawarai T, Izumi Y, Kazuta T, Oda M, Komure O, Udaka F, Kameyama M, Nakamura S, Kawakami H (2000) A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease. Ann Neurol 47:528-531
73. Muller DJ, Schulze TG, Macciardi F, Ohlraun S, Gross MM, Bauer I, Scherk H, Kischkel E, Neidt H, Syagailo YV, Grassle M, Nothen MM, Maier W, Lesch KP, Rietschel M (2000) Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase - A promoter. Eighth World Congress on Psychiatric Genetics. Neuropsychiatrie Genetics, vol 96(4). Wiley-Liss, Versailles, France, p 537
74. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL (2001) The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder. Arch Gen Psychiatry 58:539-544
75. Murphy G, Hollander S, Rodrigues H, Schatzberg A (2003a) Effects of the serotonin transporter promoter polymorphism on paroxetine and mirtazapine efficacy and side effects in geriatric major depression. In: Hospital TZH (ed) Pharmacogenetics in psychiatry meeting, vol 1, New York
76. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF (2003b) Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160:1830-1835
77. Nakagawa Y, Sasaki A, Takashima T (1999) The GABA(B) receptor antagonist CGP36742 improves learned helplessness in rats. Eur J Pharmacol 381:1-7
78. Nalepa I, Kreiner G, Kowalska M, Sanak M, Zelek-Molik A, Vetulani J (2002) Repeated imipramine and electroconvulsive shock increase alpha(1A)-adrenoceptor mRNA level in rat prefrontal cortex. Eur J Pharmacol 444:151-159
79. Neer EJ (1995) Heterotrimeric G proteins: organizers of transmembrane signals. Cell 80:249-257
80. Nielsen DA, Jenkins GL, Stefanisko KM, Jefferson KK, Goldman D (1997) Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7. Brain Res Mol Brain Res 45:145-148
81. Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwin GM, Smith CAD (1996) Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 347:731-733
82. Owen D, Du L, Bakish D, Lapierre YD, Hrdina PD (1999) Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Res 87:1-5
83. Pacholczyk T, Blakely RD, Amara SG (1991) Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350:350-354
84. Paoloni-Giacobino A, Mouthon D, Lambercy C, Vessaz M, Coutant-Zimmerli S, Rudolph W, Malafosse A, Buresi C (2000) Identification and analysis of new sequence variants in the human tryptophan hydroxylase (TpH) gene. Mol Psychiatry 5:49-55
85. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F (1997) Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349:1594-1597
86. Perlis R, Smoller J, Wan Y, Mischoulon D, Lamon-Fava S, Lin K, Rosenbaum J, Fava M (2003) Serotonin transporter plymorphisms and adverse effects with fluoxetine treatment. In: Hospital TZH (ed) Pharmacogenetics in psychiatry meeting, vol 1, New York
87. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP (2003) Pharmacogenomic analysis of five serotonergic pathway genes in antidepressant response. II Annual Pharmacogenetics in Psychiatry Meeting, New York
88. Pokk P, Vali M (2002a) Effects of nitric oxide synthase inhibitors 7-NI, L-NAME, and L-NOARG in staircase test. Arch Med Res 33:265-268
89. Pokk P, Vali M (2002b) The effects of the nitric oxide synthase inhibitors on the behaviour of small-platform-stressed mice in the plus-maze test. Prog Neuropsychopharmacol Biol Psychiatry 26:241-247
90. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ (2000) Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23:587-590
91. Polymeropoulos MH, Xiao H, Rath DS, Merril CR (1991) Tetranucleotide repeat polymorphism at the human tyrosine hydroxylase gene (TH). Nucl Acids Res 19:3753
92. 4 receptor activation inhibits presynaptically glutamatergic neurotransmission in the rat supraoptic nucleus. J Neurophysiol 86:1149-1155
93. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD (1993) Antidepressant-and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 90:2542-2546
94. Rausch JL, Johnson ME, Fei Y-J, Li JQ, Shendarkar N, MacHobby H, Ganapathy V, Leibach FH (2002) Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 51:723-732
95. 1-adrenergic receptors. J Physiol Pharmacol 53:105-116
96. Rotondo A, Schuebel KE, Bergen AW, Aragon R, Virkkunen M, Linnoila M, Goldman D, Nielsen DA (1999) Identification of four variants in the tryptophan hydroxylase promoter and association to behavior. Mol Psychiatry 4:360-368
97. 4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell 90:991-1001
98. Sabol SZ, Hu S, Hamer D (1998) A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 103:273-279
99. Sato K, Yoshida K, Takahashi H, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K (2002) Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 46:136-140
100. Serretti A, Lattuada E, Zanardi R, Franchini L, Smeraldi E (2000) Patterns of symptom improvement during antidepressant treatment of delusional depression. Psychiatry Res 94:185-190
101. 4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Res 104:195-203
102. Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E (2001b) Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 11:375-380
103. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E (2001c) Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 6:586-592
104. 3 variants. Eur Neuropsychopharmacol 13:117-22
105. Siffert W, Rosskopf D, Moritz A, Wieland T, Kaldenberg-Stasch S, Kettler N, Hartung K, Beckmann S, Jakobs KH (1995) Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. J Clin Invest 96:759-766
106. Skrebuhhova T, Allikmets L, Matto V (1999) Effects of anxiogenic drugs in rat forced swimming test. Meth Find Exp Clin Pharmacol 21:173-178
107. Small KM, Liggett SB (2001) Identification and functional characterization of alpha(2)-adrenoceptor polymorphisms. Trends Pharmacol Sci 22:471-477
108. Smeraldi E, Zanardi R, Benedetti F, Dibella D, Perez J, Catalano M (1998) Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508-511
109. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea T, Coryell W, Warshaw M, Turvey C, Maser JD, Endicott J (2000) Multiple recurrences of major depressive disorder. Am J Psychiatry 157:229-233
110. Sparkes RS, Lan N, Klisak I, Mohandas T, Diep A, Kojis T, Heinzmann C, Shih JC (1991) Assignment of a serotonin 5HT-2 receptor gene (HTR2) to human chromosome 13q14-q21 and mouse chromosome 14. Genomics 9:461-465
111. Speight G, Turic D, Austin J, Hoogendoorn B, Cardno AG, Jones L, Murphy KC, Sanders R, McCarthy G, Jones I, McCandless F, McGuffin P, Craddock N, Owen MJ, Buckland P, O'Donovan MC (2000) Comparative sequencing and association studies of aromatic L-amino acid decarboxylase in schizophrenia and bipolar disorder. Mol Psychiatry 5:327-331
112. Stahl SM (1998) Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 59:5-14
113. Steimer W, Muller B, Leucht S, Kissling W (2001) Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 308:33-41
114. Stober G, Nothen MM, Porzgen P, Bruss M, Bonisch H, Knapp M, Beckmann H, Propping P (1996) Systematic search for variation in the human norepinephrine transporter gene: identification of five naturally occurring missense mutations and study of association with major psychiatric disorders. Am J Med Genet 67:523-532
115. Szabo ST, de Montigny C, Blier P (1999) Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol 126:568-571
116. Takahashi H, Yoshida K, Ito K, Sato K, Kamata M, Higuchi H, Shimizu T, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K (2002) No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol 12:477
117. Tsai SJ, Wang YC, Hong CJ (2002) Norepinephrine transporter and alpha(2c) adrenoceptor allelic variants and personality factors. Am J Med Genet 114:649-651
118. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ (2003) Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet 123B:19-22
119. Tsuang M, Faraone S (1990) The genetics of mood disorders. Johns Hopkins University Press, Baltimore, pp 1-31
120. Uhr M, Steckler T, Yassouridis A, Holsboer F (2000) Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22:380-387
121. Van de Kar LD, Raap DK, Battaglia G, Muma NA, Garcia F, DonCarlos LL (2002) Treatment of cycling female rats with fluoxetine induces desensitization of hypothalamic 5-HT(1A) receptors with no change in 5-HT(2A) receptors. Neuropharmacology 43:45-54
122. Vetulani J, Nalepa I (2000) Antidepressants: past, present and future. Eur J Pharmacol 405:351-363
123. Volke V, Soosaar A, Koks S, Bourin M, Mannisto PT, Vasar E (1997) 7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety. Psychopharmacology 131:399-405
124. Walther DJ, Bader M (2003) A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 66:1673-1680
125. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, Bader M (2003) Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299:76
126. Wei J, Ramchand CN, Hemmings GP (1996) A study of the relationship between the DBH activity in serum and a MspI polymorphic site in intron 9 of the human DBH gene in schizophrenia. Schizophr Res 22:77-80
127. Wood JG, Joyce PR, Miller AL, Mulder RT, Kennedy MA (2002) A polymorphism in the dopamine beta-hydroxylase gene is associated with "paranoid ideation" in patients with major depression. Biol Psychiatry 51:365-369
128. 1A receptor gene. Psychiatr Genet 9:105-106
129. Wu WH, Huo SJ, Cheng CY, Hong CJ, Tsai SJ (2001) Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 44:172-175
130. Yang-Feng TL, Xue FY, Zhong WW, Cotecchia S, Frielle T, Caron MG, Lefkowitz RJ, Francke U (1990) Chromosomal organization of adrenergic receptor genes. Proc Natl Acad Sci USA 87:1516-1520
131. Yang-Feng TL, Han H, Lomasney JW, Caron MG (1994) Localization of the cDNA for an alpha 1-adrenergic receptor subtype (ADRA1D) to chromosome band 20p13. Cytogenet Cell Genet 66:170-171
132. Yildiz F, Erden BF, Ulak G, Utkan T, Gacar N (2000) Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology 149:41-44
133. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K (2002a) Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 26:383-386
134. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K (2002b) Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 26:1279-1283
135. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ (2002) Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7:1115-1119
136. Yu YW, Chen TJ, Hong CJ, Chen HM, Tsai SJ (2003a) Association study of the interleukin-1beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology 28:1182-1185
137. Yu YW, Chen TJ, Wang YC, Liou YJ, Hong CJ, Tsai SJ (2003b) Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response. Neuropsychobiology 47:137-140
138. Zabetian CP, Anderson GM, Buxbaum SG, Elston RC, Ichinose H, Nagatsu T, Kim KS, Kim CH, Malison RT, Gelernter J, Cubells JF (2001) A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet 68:515-522
139. Zanardi R, Benedetti F, DiBella D, Catalano M, Smeraldi E (2000) Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol 20:105-107
140. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E (2001) Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50:323-330
141. Zangen A, Nakash R, Overstreet DH, Yadid G (2001) Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens. Psychopharmacology 155:434-439
142. Zarrindast M, Valizadeh S, Sahebgharani M (2000) GABA(B) receptor mechanism and imipramine-induced antinociception in ligated and non-ligated mice. Eur J Pharmacol 407:65-72
143. Zill P, Baghai TC, Zwanzger P, Schule C, Minov C, Riedel M, Neumeier K, Rupprecht R, Bondy B (2000) Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 11:1893-1897
144. Zill P, Baghai TC, Engel R, Zwanzger P, Schule C, Minov C, Behrens S, Bottlender R, Jager M, Rupprecht R, Moller HJ, Ackeneil M, Bondy B (2002a) The beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment. In: Tsuang M (ed) Xth World Congress of Psychiatric Genetics, vol 114. Wiley-Liss, Brussels, p 777
145. Zill P, Engel R, Baghai TC, Juckel G, Frodl T, Muller-Siecheneder F, Zwanzger P, Schule C, Minov C, Behrens S, Rupprecht R, Hegerl U, Moller HJ, Bondy B (2002b) Identification of a naturally occurring polymorphism in the promoter region of the norepinephrine transporter and analysis in major depression. Neuropsychopharmacology 26:489-493
146. Zill P, Baghai TC, Engel R, Zwanzger P, Schule C, Minov C, Behrens S, Bottlender R, Jager M, Rupprecht R, Moller HJ, Ackenheil M, Bondy B (2003) Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response. Am J Med Genet 120B:85-89